Zhuang Hong-Qing, Yuan Zhi-Yong
Department of Radiotherapy, Tianjin Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, PR China.
Cancer Lett. 2009 Sep 8;282(1):9-13. doi: 10.1016/j.canlet.2008.12.008. Epub 2009 Jan 10.
Endostatin has been demonstrated to represent a promising novel medicine to treat malignant tumors, and it may be more effective when combined with conventional treatment. Meanwhile, a promising area of research in radiation oncology is the integration of molecular targeting agents to improve the effectiveness of radiotherapy (RT) in the control of primary tumor. Antiangiogenic agents are one such class of targeted therapies and have shown promise in both laboratory and clinical experiments. Endostatin in combination with RT has feasibility; but it also has lots of problems. Further understanding of the mechanisms is needed.
内皮抑素已被证明是一种有前景的治疗恶性肿瘤的新型药物，与传统治疗联合使用时可能更有效。同时，放射肿瘤学一个有前景的研究领域是整合分子靶向药物以提高放射治疗（RT）对原发性肿瘤的控制效果。抗血管生成药物就是这类靶向治疗药物之一，并且在实验室和临床实验中都已显示出前景。内皮抑素与放疗联合使用具有可行性；但也存在许多问题。需要进一步了解其机制。
